CVRx Announces Appointment of Two New Board Members
CVRx, Inc. (NASDAQ: CVRX) has announced significant changes to its Board of Directors. Kevin Ballinger and Mitch Hill have been appointed as new independent board members, effective immediately. Ballinger brings over 25 years of experience in the medical device industry, including leadership roles at Aldevron and Boston Scientific. Hill contributes more than 30 years of financial and operational experience in healthcare and technology sectors, most recently as CFO of Inari Medical.
Concurrently, long-serving board member Ali Behbahani is departing. These changes result in a seven-member Board of Directors for CVRx. The company expects the new appointments to support its strategic goals, particularly in expanding the adoption of its Barostim therapy for heart failure patients.
CVRx, Inc. (NASDAQ: CVRX) ha annunciato significative modifiche al suo Consiglio di Amministrazione. Kevin Ballinger e Mitch Hill sono stati nominati nuovi membri indipendenti del consiglio, con effetto immediato. Ballinger porta con sé oltre 25 anni di esperienza nell'industria dei dispositivi medici, compresi ruoli di leadership in Aldevron e Boston Scientific. Hill contribuisce con oltre 30 anni di esperienza finanziaria e operativa nei settori della salute e della tecnologia, più recentemente come CFO di Inari Medical.
Contemporaneamente, il membro di lungo corso del consiglio Ali Behbahani si sta ritirando. Queste modifiche portano il Consiglio di Amministrazione di CVRx a sette membri. L'azienda si aspetta che le nuove nomine supportino i suoi obiettivi strategici, in particolare nell'espansione dell'adozione della terapia Barostim per i pazienti con insufficienza cardiaca.
CVRx, Inc. (NASDAQ: CVRX) ha anunciado cambios significativos en su Junta Directiva. Kevin Ballinger y Mitch Hill han sido nombrados nuevos miembros independientes de la junta, con efecto inmediato. Ballinger aporta más de 25 años de experiencia en la industria de dispositivos médicos, incluidos roles de liderazgo en Aldevron y Boston Scientific. Hill contribuye con más de 30 años de experiencia financiera y operativa en los sectores de salud y tecnología, siendo más reciente CFO de Inari Medical.
Al mismo tiempo, el miembro de larga data de la junta Ali Behbahani está dejando su puesto. Estos cambios dan como resultado una Junta Directiva de siete miembros para CVRx. La empresa espera que los nuevos nombramientos apoyen sus objetivos estratégicos, especialmente en la expansión de la adopción de la terapia Barostim para pacientes con insuficiencia cardíaca.
CVRx, Inc. (NASDAQ: CVRX)가 이사회의 중요한 변화를 발표했습니다. Kevin Ballinger와 Mitch Hill가 즉시 효력을 발휘하는 새로운 독립 이사로 임명되었습니다. Ballinger는 Aldevron과 Boston Scientific에서의 리더십 역할을 포함하여 의료 기기 산업에서 25년 이상의 경험을 가지고 있습니다. Hill은 최근 Inari Medical의 CFO로 재직했으며, 의료 및 기술 분야에서 30년 이상의 재무 및 운영 경험을 제공합니다.
동시에 오랜 이사인 Ali Behbahani가 떠나게 됩니다. 이러한 변화로 CVRx의 이사회 구성원은 총 7명이 됩니다. 회사는 새로운 임명이 특히 심부전 환자를 위한 Barostim 치료법의 채택 확대에서 전략적 목표를 지원할 것으로 기대하고 있습니다.
CVRx, Inc. (NASDAQ: CVRX) a annoncé des changements importants au sein de son conseil d'administration. Kevin Ballinger et Mitch Hill ont été nommés nouveaux membres indépendants du conseil, avec effet immédiat. Ballinger apporte plus de 25 ans d'expérience dans l'industrie des dispositifs médicaux, y compris des fonctions de direction chez Aldevron et Boston Scientific. Hill contribue quant à lui avec plus de 30 ans d'expérience financière et opérationnelle dans les secteurs de la santé et de la technologie, le plus récemment en tant que CFO d'Inari Medical.
En parallèle, Ali Behbahani, membre de longue date du conseil, se retire. Ces changements font que le conseil d'administration de CVRx compte désormais sept membres. L'entreprise s'attend à ce que les nouvelles nominations soutiennent ses objectifs stratégiques, notamment en élargissant l'adoption de la thérapie Barostim pour les patients souffrant d'insuffisance cardiaque.
CVRx, Inc. (NASDAQ: CVRX) hat bedeutende Änderungen im Vorstand angekündigt. Kevin Ballinger und Mitch Hill wurden mit sofortiger Wirkung zu neuen unabhängigen Vorstandsmitgliedern ernannt. Ballinger bringt über 25 Jahre Erfahrung in der Medizintechnik mit, einschließlich Führungspositionen bei Aldevron und Boston Scientific. Hill bringt mehr als 30 Jahre an finanzieller und operativer Erfahrung im Gesundheits- und Technologiesektor mit, zuletzt als CFO von Inari Medical.
Gleichzeitig scheidet das langjährige Vorstandsmitglied Ali Behbahani aus. Diese Änderungen führen zu einem siebenköpfigen Vorstand für CVRx. Das Unternehmen erwartet, dass die neuen Ernennungen seine strategischen Ziele unterstützen, insbesondere die Ausweitung der Anwendung der Barostim-Therapie für Herzinsuffizienzpatienten.
- Appointment of two experienced industry leaders to the Board of Directors
- Kevin Ballinger brings expertise in interventional cardiology and global commercialization
- Mitch Hill contributes significant financial acumen from high-growth healthcare companies
- Board restructuring aligns with CVRx's strategic goals for Barostim therapy expansion
- Departure of long-serving board member Ali Behbahani
Kevin Ballinger and Mitch Hill appointed as new independent Board members
MINNEAPOLIS, Sept. 03, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced the appointments of Kevin Ballinger and Mitch Hill to its Board of Directors, effective immediately. The Company also announced that long-serving board member Ali Behbahani will be leaving the board. Following these changes, the Company’s Board of Directors consists of seven members.
"We are thrilled to welcome Kevin and Mitch to our Board of Directors," said Kevin Hykes, President and CEO of CVRx. "Their extensive experience in the medical device industry, coupled with their strong track records driving growth and innovation, will be invaluable as we continue to expand the adoption of our Barostim therapy. Kevin's deep understanding of interventional cardiology and Mitch's financial acumen in high-growth healthcare companies align perfectly with our strategic goals.”
Kevin Ballinger brings over 25 years of experience in the medical device industry, most recently serving as the Chief Executive Officer of Aldevron, LLC, where he successfully led the company through a period of rapid growth and its subsequent acquisition by Danaher Corporation. Prior to that, he spent over two decades at Boston Scientific Corporation in various leadership roles, including Executive Vice President and Global President of Interventional Cardiology. Ballinger's expertise spans product development, global commercialization, and strategic planning in the cardiovascular space. He currently serves on the board of directors of Silk Road Medical, Inc., and, prior to its acquisition by Johnson & Johnson earlier this year, served on the board of directors of Shockwave Medical, Inc.
Mitch Hill joins the board with over 30 years of financial and operational experience in the healthcare and technology sectors. He is retiring as the Chief Financial Officer of Inari Medical, Inc., effective October 1, having led the company through its initial public offering and a period of significant growth. Prior to Inari, Hill held executive positions at Cameron Health, Inc. and Visiogen Inc., both of which were acquired during his tenure. Hill also held leadership roles at Walt Disney Imagineering and Disney Development Co.
The Company also announced that Ali Behbahani, General Partner of New Enterprise Associates, who has served on the board since 2013, is leaving the board. “On behalf of CVRx and the Board of Directors, I would like to thank Ali for his tireless support of the company throughout much of our long history. His expertise and dedication have been instrumental in the development and commercialization of Barostim therapy, which has had a positive impact on thousands of patients suffering from heart failure,” said Kevin Hykes, President and Chief Executive Officer of CVRx.
About CVRx, Inc.
CVRx is focused on the development and commercialization of the Barostim™ System, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body's baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
Investor Contact:
Mark Klausner or Mike Vallie
ICR Westwicke
443-213-0501
ir@cvrx.com
Media Contact:
Laura O’Neill
Finn Partners
402-499-8203
laura.oneill@finnpartners.com
FAQ
Who are the new board members appointed to CVRx (CVRX)?
What experience does Kevin Ballinger bring to CVRx's (CVRX) board?
What is Mitch Hill's background in relation to his appointment to CVRx's (CVRX) board?
How many members are on CVRx's (CVRX) Board of Directors after these changes?
What is the strategic focus of CVRx (CVRX) mentioned in relation to these board appointments?
